Sign inCreate account

Report workspace tools

NCT00954252COMPLETEDanonymous

Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects

Sponsor

Source record

CERESPIR

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.

Indication / condition

AI-normalized

Alzheimer's Disease

Intervention

Source record

CHF 5074, placebo, CHF 5074, CHF 5074, CHF 5074, CHF 5074, CHF 5074

Source & freshness

Source record

NCT ID

NCT00954252

Original source

ClinicalTrials.gov

Source last updated

Feb 10, 2015

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00954252

Title

Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects

Sponsor

CERESPIR

Status

COMPLETED

Phase

Phase 1

Condition raw

Alzheimer's Disease

Condition normalized

Alzheimer's Disease

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.

Target normalized

Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.

Interventions

CHF 5074, placebo, CHF 5074, CHF 5074, CHF 5074, CHF 5074, CHF 5074

Public preview

Source record

CHF 5074, developed by CERESPIR, is positioned as a novel gamma-secretase modulator aimed at treating Alzheimer's disease by reducing amyloid-beta levels. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. The competitive landscape includes several established players and emerging biotech firms focused on similar mechanisms. Given the high unmet need in Alzheimer's treatment, successful outcomes in this trial could enhance CERESPIR's market position and attract potential partnerships or acquisition interest. Diligence should focus on the safety profile and pharmacokinetic data to assess viability for further development.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00954252

Status

COMPLETED

Phase

Phase 1

Sponsor

CERESPIR

Executive brief

Investment-Ready Snapshot

CHF 5074, developed by CERESPIR, is positioned as a novel gamma-secretase modulator aimed at treating Alzheimer's disease by reducing amyloid-beta levels. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. The competitive landscape includes several established players and emerging biotech firms focused on similar mechanisms. Given the high unmet need in Alzheimer's treatment, successful outcomes in this trial could enhance CERESPIR's market position and attract potential partnerships or acquisition interest. Diligence should focus on the safety profile and pharmacokinetic data to assess viability for further development.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 10, 2015
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00954252

Indication

Alzheimer's Disease

Modality

small molecule

Target

Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.

Intervention

CHF 5074, placebo, CHF 5074, CHF 5074, CHF 5074, CHF 5074, CHF 5074

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.